Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose versus standard-dose caffeine for apnea of prematurity
ACTRN12619001708145Phase 2Recruiting
- Sponsor
- Hospital Universiti Sains Malaysia
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of caffeine in apnea of prematurity (AOP) (2 arms), sponsored by Hospital Universiti Sains Malaysia. Primary endpoints: Frequency of apnea during treatment and Total number of days with apnea. Started Jun 2019; status: recruiting.
02
Drugs
caffeine
03
Conditions
apnea of prematurity (AOP)
Beyond the preview
Go deeper on ACTRN12619001708145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001708145.